Patent Litigation Europe returns to Amsterdam with IPKat readers’ discount

Kats of Amsterdam

The Katfriends at Kisaco Research wish to inform IPKat readers that their Patent Litigation Europe event is returning to the Beurs van Berlage in Amsterdam on 18-20 January 2027. The agenda is available here.

As explained by the organizers, following a successful rebrand this year, Patent Litigation Europe 2027 retains three co-located tracks – UPC Litigation Forum, Pharma & Biotech Patent Litigation and Tech & Innovation Patent Litigation – with 850+ attendees, 45% in-house counsel and 20+ networking hours across three days for meeting new clients and building referral relationships.

What’s new for 2027:
  • A bigger stage for the UPC Litigation Forum: Two full tracks cover emerging strategy and case law, alongside integrating the UPC into the global IP industry.
  • Specialist workshops: Dedicated, smaller-format sessions on MedTech, trade secrets, and soft IP built for deep discussions on key issues of interest for the participants and their clients.
  • New frontiers in technology litigation: Expanded coverage across the tech and innovation agenda, including MedTech patenting concerns, SEP/FRAND, AI and quantum computing and NPE Litigation.
  • The full scope of pharma & biotech IP: Innovator disputes, secondary patents, manufacturing litigation, parallel proceedings and biosimilars, that is what in-house teams are focusing on today.
  • Sharper global context: Perspectives from the U.S., Canada, Brazil, China and beyond, reflecting the need for trusted cross-border relationships and integrated international litigation support from patent attorneys providing necessary technical perspectives on cases.
Speakers include:

UPC Litigation Forum, 18 January 2027
  • Hon. Emmanuel Gouge – UPC Court of Appeals
  • Clemens Heusch – Nokia
  • Ewan Nettleton – Novartis
  • Erich Spangenberg – SIM IP
  • Mark Blake – Medtronic
Pharma & Biotech Patent Litigation, 19-20 January 2027
  • Oliver Schön – Munich Regional Court
  • Daniela Gill-Carey – Astellas Pharma
  • Julia Pike – Sandoz
  • Mathilde Rauline – Sanofi
  • Mark Stewart – MSD
Tech & Innovation Patent Litigation, 19-20 January 2027
  • Chammika Subasinghe – Rakuten Group
  • Gabriele Mohsler – Ericsson
  • Gael Tisack – Abbott
  • Rebecca Brown – Sonos
  • Nobuo Tanaka – Yokogawa Electric Corporation
According to the organizers, participation in the Summit will allow to: access practical, international content; build tailored commercial connections with a 45% senior in-house audience, alongside global law firms; address key concerns to take to client work; meet global disputes and patent attorney teams to gain technical expert and cross-border referrals.

Early Bird pricing is running until tomorrow (18 September), and IPKat readers are entitled to a 10% discount on top of the current Early Bird rate, using code IPKat at checkout. Click here to register.
Patent Litigation Europe returns to Amsterdam with IPKat readers’ discount Patent Litigation Europe returns to Amsterdam with IPKat readers’ discount Reviewed by Eleonora Rosati on Thursday, September 17, 2026 Rating: 5

No comments:

All comments must be moderated by a member of the IPKat team before they appear on the blog. Comments will not be allowed if the contravene the IPKat policy that readers' comments should not be obscene or defamatory; they should not consist of ad hominem attacks on members of the blog team or other comment-posters and they should make a constructive contribution to the discussion of the post on which they purport to comment.

It is also the IPKat policy that comments should not be made completely anonymously, and users should use a consistent name or pseudonym (which should not itself be defamatory or obscene, or that of another real person), either in the "identity" field, or at the beginning of the comment. Current practice is to, however, allow a limited number of comments that contravene this policy, provided that the comment has a high degree of relevance and the comment chain does not become too difficult to follow.

Learn more here: http://ipkitten.blogspot.com/p/want-to-complain.html

Powered by Blogger.